Table 2.
General features of the trials
| Trials | No of patients treated with 10 mg empagliflozin (n) | No of patients treated with 25 mg empagliflozin (n) | Enrollment period | Type of study | Bias risk gradea |
|---|---|---|---|---|---|
| Araki et al. [7] | 548 | 549 | 2011–2013 | RCT | B |
| Ferrannini et al. [8] | 272 | 275 | 2009–2011 | RCT | B |
| Haring et al. [9] | 217 | 213 | 2010–2012 | RCT | B |
| Kadowaki et al. [10] | 267 | 265 | 2010–2014 | RCT | B |
| Roden et al. [11] | 224 | 223 | 2010–2012 | RCT | A |
| Softeland et al. [12] | 112 | 110 | 2013–2015 | RCT | B |
| Takkanen et al. [13] | 276 | 276 | 2011–2012 | RCT | B |
| Zinman et al. [14] | 2345 | 2342 | 2010–2013 | RCT | A |
| Total no of patients (n) | 4261 | 4253 |
RCT Randomized controlled trials
aGrade A suggests very low risk of bias; grade E suggests a high risk of bias.